

clinical practice guidelines

Annals of Oncology 23 (Supplement 7): vii83–vii85, 2012
doi:10.1093/annonc/mds266

Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[†]

A.T.C. Chan¹, V. Grégoire², J.-L. Lefebvre³, L. Licitra⁴, E.P. Hui¹, S.F. Leung¹ & E. Felip⁵, on behalf of the EHNS–ESMO–ESTRO Guidelines Working Group*

¹Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong;

²Department of Radiation Oncology, St-Luc University Hospital, Brussels, Belgium; ³Department of Head and Neck Surgery, Centre Oscar Lambret, Lille, France;

⁴Medical Oncology Head and Neck Unit, Istituto Nazionale dei Tumori, Milan, Italy; ⁵Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain

incidence

Cancer of the nasopharynx (NPC) is rare in Europe, with an annual crude incidence rate of 1.1 per 100 000. On the European scale, NPC accounts for 4760 new cases per year. Incidence is higher in men than women. [1, 2].

In Europe, the relative survival for NPC was 76% at 1 year and 50% at 5 years in adults. There were no survival differences between the sexes. The effect of age on survival is marked. Survival at 5 years was 72% for the youngest age group (15–45 years) and 36% in the oldest group of patients (65–74 years) [1, 2].

diagnosis

Definitive diagnosis is made by endoscopic-guided biopsy of the primary nasopharyngeal tumor. The histological type should be classified according to World Health Organization (WHO) classification [3]. Since the first disease sign in patients is often the appearance of neck nodes it is not infrequent that patients undergo neck biopsy and/or neck nodal dissection. This procedure is not recommended since it may reduce cure probability and have an impact on late treatment sequelae.

staging and risk assessment

NPC is clinically staged according to the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system (Table 1). Routine staging procedures include history, physical

examination including cranial nerve examination, complete blood cell count, serum biochemistry (including liver function test), chest X-ray, nasopharyngoscopy, computed tomography (CT) scan or magnetic resonance imaging (MRI) of nasopharynx and base of skull and neck. Although MRI is generally preferred if available, each center will choose the best imaging technique according to their usual clinical practice and experience [III, B]. Imaging for distant metastases including isotope bone scan and CT scan of chest and upper abdomen could be considered for at-risk subsets (node positive, especially N3 stage) and for those patients with clinical or biochemical abnormalities detected [III, B]. The use of positron emission tomography CT scan can replace the traditional work-up for detection of distant metastatic disease since it has proved to be the most sensitive, specific and accurate diagnostic method. Both the pre-treatment and post-treatment plasma/serum load of Epstein-Barr viral DNA has been shown to be of prognostic value [III, B] [4–8].

treatment

The optimal treatment strategy of patients with advanced NPC should be discussed in a multidisciplinary team. Radiation therapy (RT) is the mainstay of treatment and is an essential component of curative-intent treatment of non-disseminated NPC. Stage I disease is treated by RT alone, while stage III, IVA, IVB disease are treated by RT with concurrent chemotherapy [I, A]. Concurrent chemotherapy is recommended for stage II disease [I, B] [9]. Patients should be treated by intensity-modulated radiation therapy (IMRT) [II, A] [10]. RT is targeted to the primary tumor and the adjacent regions considered at risk of microscopic spread from the tumor, and to both the sides of the neck (levels Ib–V, and retropharyngeal nodes). For patients with lower neck nodes, the supraclavicular fossa should be included as well. Elective nodal irradiation is recommended for N0 stage disease. The consensus is that a total dose of 70 Gy is needed for

*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalguidelines@esmo.org

[†]Approved by the ESMO Guidelines Working Group: December 2006, last update June 2012. This publication supersedes the previously published version—*Ann Oncol* 2010; 21 (Suppl 5): v187–v189.

Table 1. The International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system for NPC, seventh edition (2010)

Primary tumor (T)				
T1	Tumor confined to the nasopharynx, or extends to oropharynx and/or nasal cavity without parapharyngeal extension			
T2	Tumor with parapharyngeal extension			
T3	Tumor involves bony structures of skull base and/or paranasal sinuses			
T4	Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space			
Regional lymph nodes (N)				
N1	Unilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, ≤6 cm, in greatest dimension			
N2	Bilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa			
N3	Metastasis in a lymph node(s) >6 cm and/or to supraclavicular fossa			
N3a	>6 cm in dimension			
N3b	Extension to the supraclavicular fossa			
Distant metastasis (M)				
M0	No distant metastasis			
M1	Distant metastasis			
Anatomic stage/prognostic groups				
Stage 0	Tis		N0	M0
Stage I	T1		N0	M0
Stage II	T1		N1	M0
	T2		N0	M0
	T2		N1	M0
	T2		N2	M0
Stage III	T1		N2	M0
	T2		N2	M0
	T3		N0	M0
	T3		N1	M0
	T3		N2	M0
Stage IVA	T4		N0	M0
	T4		N1	M0
	T4		N2	M0
	T4		N3	M0
Stage IVB	Any T		N3	M0
Stage IVC	Any T		Any N	M1

eradication of gross tumor and either 50–60 Gy or 46–60 Gy for elective treatment of potential risk sites. To minimize the risk of late toxicity (particularly, to adjacent neurological structures), fractional dose >2 Gy per daily fraction and excessive acceleration with multiple fractions >1.9 Gy/fraction should be avoided [III, E]. IMRT may offer improvement in local tumor control [II, A], and reduction in radiation xerostomia in early-stage disease [II, A]. The standard agent used in concurrent chemotherapy–RT is cisplatin [I, A]. This provides a benefit in terms of overall survival and on both locoregional and distant control [9, 11–15]. While three cycles of adjuvant cisplatin-5FU has been a standard part of many concurrent chemoradiotherapy regimens, its benefit is uncertain and toxic effect is substantial [16]. Cisplatin-based induction chemotherapy has been shown to improve disease-free survival and may be considered in locally advanced disease although it is not seen as a standard treatment [II, B] [17]. In no case should induction

chemotherapy negatively affect the optimal administration of concomitant chemoradiation.

follow-up

Documentation of complete remission in the nasopharynx and neck through clinical and endoscopic examination and/or imaging studies is important. MRI is often used to evaluate the response to RT or chemoradiotherapy, especially for T3 and T4 tumors, though distinction between post-irradiation changes and recurrent tumors may be difficult. Follow-up for patients includes periodic examination of the nasopharynx and neck, cranial nerve function and evaluation of systemic complaints to identify distant metastasis. For T3 and T4 tumors, MRI might be used on a 6- to 12-month basis to evaluate the nasopharynx and the base of the skull at least for the first few years after treatment. Evaluation of thyroid function in patients with irradiation to the neck is recommended at 1, 2 and 5 years.

treatment of recurrent or metastatic disease

Small local recurrences are potentially curable and the main issue is the choice of the most appropriate therapeutic options, which include nasopharyngectomy, brachytherapy, radiosurgery, stereotactic RT, IMRT or a combination of surgery and RT, with or without concurrent chemotherapy. Treatment decisions are tailored to the specific situation of individual cases, taking into consideration the volume, location and extent of the recurrent tumor [III, A]. Regional recurrence is managed by radical neck dissection if resectable [III, A].

In metastatic NPC, palliative chemotherapy should be considered for patients with adequate performance status. Platinum combination regimens are commonly used as first-line therapy since cisplatin represents the most effective drug. Other active agents include paclitaxel, docetaxel, gemcitabine, capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin and oxaliplatin, which can be used as single agents or in combination [III, B]. Polychemotherapy is more active than monotherapy. In this context treatment choice should be based on previous treatments and the expected toxicity [18].

Table 2 Summary of treatment recommendations for Cancer of the nasopharynx (NPC)

Early stage	Stage I	Radiation alone
Intermediate stage	Stage II	Concurrent chemoradiotherapy (I, B)
Advanced stage	Stage III, IVA, IVB	Concurrent chemoradiotherapy +/- adjuvant chemotherapy (I, A)
Problematic radiation therapy (RT) planning (e.g. tumor abutting chiasm)	Stage IVA, IVB	Induction chemotherapy followed by concurrent chemoradiotherapy (II, B)

notes

Levels of evidence [I–V] and grades of recommendation [A–E] adapted from the Infectious Diseases Society of American–United States Public Health Service Grading System are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts.

conflict of interest

Prof. Lefebvre has reported: lecturer and advisory board for Merck Serono and Sanofi-Aventis. Dr. Licitra has reported: advisory board of Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Merck Serono and Amgen; institution has received clinical and research support from EISAI, Exelixis, Lilly, Merck-Serono, Amgen; and travel support from Merck Serono. Prof. Chan has reported receiving honoraria and research support from Merck-Serono, Amgen, Novartis, Roche, Pfizer and SanofiAventis. Dr. Felip has reported: consultancy/honoraria from Lilly, GlaxoSmithKline, Merck Serono, Roche, Boehringer

Ingelheim. Dr. Hui has reported: consultancy and advisory board for Sanofi-Aventis and Pfizer. Prof. Grégoire has reported no conflicts of interest.

references

- Curado MP, Edwards B, Shin HR et al. (eds). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC 2007.
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press 2004.
- Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press 2005.
- Chua DT, Ji M, Zong Y et al. Screening of nasopharyngeal carcinoma by serology and nasopharyngoscopy and treatment outcome in endemic region. *J Clin Oncol* 2009; 27: 15s.
- Chua ML, Ong SC, Wee JT et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. *Head Neck* 2009; 31: 346–354.
- Chan AT, Lo YM, Zee B et al. Plasma Epstein–Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. *J Natl Cancer Inst* 2002; 94: 1614–1619.
- Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. *N Engl J Med* 2004; 350 (24): 2461.
- Leung SF, Zee B, Ma BB et al. Plasma Epstein–Barr viral deoxyribonucleic acid quantitation complements TNM staging in nasopharyngeal carcinoma prognostication. *J Clin Oncol* 2006; 34: 5414–5418.
- Chen QY, Wen YF, Guo L et al. Concurrent chemoradiotherapy vs radiotherapy alone in Stage II nasopharyngeal carcinoma: phase III randomized Trial. *J Natl Cancer Inst* 2011; 103 (23): 1761.
- Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensity modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. *J Clin Oncol* 2007; 25: 4873–4879.
- Kwong DL, Sham JS, Au GK et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. *J Clin Oncol* 2004; 22: 2643–2653.
- Chan AT, Leung SF, Ngan RK et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 2005; 97: 536–539.
- Lin JC, Jan JS, Hsu CY et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. *J Clin Oncol* 2003; 21: 631–637.
- Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. *J Clin Oncol* 2005; 23: 6730–6738.
- Lee AW, Tung SY, Chua DT et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 2010; 102 (15): 1188.
- Chen L, Hu CS, Chen XZ et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. *Lancet Oncol* 2012; 13(2): 163–171.
- Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. *J Clin Oncol* 2005; 23: 1118–1124.
- Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. *Cancer Sci* 2008; 99 (7): 1311–1318.